RNA-seq analysis regarding antiandrogen (enzalutamide) effect on gene expression in castration-resistant prostate cancer (CRPC) xenograft model

ABSTRACT: VCaP prostate cancer xenografts grown in castrated mice were treated with antiandrogen (enzalutamide), and samples were obtained during treatment response (Enza I: 5 days after initiation of the treatment) and after the treatment resistance had occurred (Enza II: 47 days after initiation of the treatment).

ORGANISM(S): Homo sapiens

PROVIDER: GSE147541 | GEO | 2022/05/02

REPOSITORIES: GEO